Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells
Open Access
- 1 April 2006
- journal article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 70 (1) , 50-60
- https://doi.org/10.1016/j.cardiores.2006.01.002
Abstract
Objective Standard drugs post-myocardial infarction (MI) such as angiotensin converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) increase levels of endothelial progenitor cells (EPC). However, potential underlying mechanisms have not yet been investigated. Methods and results We studied the effects of ACE inhibition or statin treatment on EPC levels and on bone marrow molecular pathways involved in EPC mobilization after MI in rats. Three days post-infarction, acetylated LDL (acLDL)+/Ulex europeus-1 (UEA-1)+/VEGF receptor-2+/eNOS+EPC levels and formation of endothelial colony forming units (CFU) were reduced to 60±12% (ppConclusions Increased ROS and impaired MMP-9 activity in bone marrow likely contribute to reduced EPC mobilization in the early post-infarction phase. ACE inhibition or statin treatment increased EPC levels with distinct drug-specific effects on bone marrow molecular alterations.Keywords
This publication has 0 references indexed in Scilit: